- Home
- RBOT vs MRSN Comparison
RBOT vs MRSN Comparison
Compare RBOT & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- MRSN
- Stock Information
- Founded
- RBOT 2014
- MRSN 2001
- Country
- RBOT United States
- MRSN United States
- Employees
- RBOT N/A
- MRSN N/A
- Industry
- RBOT Medical Specialities
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- MRSN Health Care
- Exchange
- RBOT Nasdaq
- MRSN Nasdaq
- Market Cap
- RBOT 42.0M
- MRSN 37.0M
- IPO Year
- RBOT N/A
- MRSN 2017
- Fundamental
- Price
- RBOT $6.94
- MRSN $9.44
- Analyst Decision
- RBOT Hold
- MRSN Strong Buy
- Analyst Count
- RBOT 1
- MRSN 3
- Target Price
- RBOT $7.00
- MRSN $33.00
- AVG Volume (30 Days)
- RBOT 90.2K
- MRSN 49.0K
- Earning Date
- RBOT 11-11-2025
- MRSN 11-12-2025
- Dividend Yield
- RBOT N/A
- MRSN N/A
- EPS Growth
- RBOT N/A
- MRSN N/A
- EPS
- RBOT N/A
- MRSN N/A
- Revenue
- RBOT N/A
- MRSN $34,769,000.00
- Revenue This Year
- RBOT N/A
- MRSN N/A
- Revenue Next Year
- RBOT N/A
- MRSN N/A
- P/E Ratio
- RBOT N/A
- MRSN N/A
- Revenue Growth
- RBOT N/A
- MRSN 16.14
- 52 Week Low
- RBOT $5.00
- MRSN $5.21
- 52 Week High
- RBOT $19.00
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- RBOT 53.76
- MRSN 62.93
- Support Level
- RBOT $5.26
- MRSN $7.85
- Resistance Level
- RBOT $7.72
- MRSN $8.35
- Average True Range (ATR)
- RBOT 0.61
- MRSN 0.37
- MACD
- RBOT 0.21
- MRSN 0.00
- Stochastic Oscillator
- RBOT 56.51
- MRSN 77.70
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.